Leerink Partners Cuts PROCEPT BioRobotics (NASDAQ:PRCT) Price Target to $30.00

PROCEPT BioRobotics (NASDAQ:PRCT) had its price objective cut by research analysts at Leerink Partners from $55.00 to $30.00 in a report issued on Thursday,Benzinga reports. The brokerage currently has an “outperform” rating on the stock. Leerink Partners’ target price indicates a potential upside of 26.90% from the company’s current price.

Other research analysts have also recently issued research reports about the stock. Truist Financial lowered their target price on shares of PROCEPT BioRobotics from $50.00 to $47.00 and set a “buy” rating for the company in a report on Thursday, December 18th. Weiss Ratings restated a “sell (e+)” rating on shares of PROCEPT BioRobotics in a research note on Thursday, January 22nd. Bank of America lowered PROCEPT BioRobotics from a “neutral” rating to an “underperform” rating and dropped their price objective for the stock from $38.00 to $20.00 in a report on Thursday. Oppenheimer reissued a “market perform” rating on shares of PROCEPT BioRobotics in a report on Thursday. Finally, TD Cowen dropped their price target on PROCEPT BioRobotics from $50.00 to $34.00 and set a “buy” rating on the stock in a research note on Thursday. One analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, two have assigned a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat, PROCEPT BioRobotics has a consensus rating of “Moderate Buy” and a consensus price target of $43.60.

PROCEPT BioRobotics Stock Down 15.1%

Shares of PROCEPT BioRobotics stock traded down $4.20 during trading on Thursday, hitting $23.64. 7,353,204 shares of the stock were exchanged, compared to its average volume of 1,382,187. The company has a debt-to-equity ratio of 0.14, a current ratio of 8.44 and a quick ratio of 7.20. The firm’s 50-day moving average price is $30.37 and its 200 day moving average price is $33.71. The stock has a market cap of $1.32 billion, a price-to-earnings ratio of -15.46 and a beta of 0.99. PROCEPT BioRobotics has a 12-month low of $19.35 and a 12-month high of $68.70.

PROCEPT BioRobotics (NASDAQ:PRCT) last posted its quarterly earnings results on Wednesday, February 25th. The company reported ($0.53) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.21). The business had revenue of $76.38 million during the quarter, compared to analyst estimates of $93.70 million. PROCEPT BioRobotics had a negative net margin of 28.20% and a negative return on equity of 21.72%. The firm’s quarterly revenue was up 11.9% on a year-over-year basis. During the same quarter in the prior year, the business earned ($0.35) earnings per share. As a group, analysts forecast that PROCEPT BioRobotics will post -1.75 earnings per share for the current fiscal year.

Hedge Funds Weigh In On PROCEPT BioRobotics

Several institutional investors and hedge funds have recently added to or reduced their stakes in PRCT. Mitsubishi UFJ Trust & Banking Corp acquired a new stake in shares of PROCEPT BioRobotics in the second quarter valued at approximately $5,892,000. Lisanti Capital Growth LLC acquired a new position in shares of PROCEPT BioRobotics during the 2nd quarter worth approximately $2,532,000. Mitsubishi UFJ Asset Management Co. Ltd. lifted its stake in PROCEPT BioRobotics by 109.3% in the 2nd quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 159,874 shares of the company’s stock valued at $9,209,000 after buying an additional 83,498 shares in the last quarter. Chicago Capital LLC grew its holdings in PROCEPT BioRobotics by 175.7% during the 3rd quarter. Chicago Capital LLC now owns 1,568,845 shares of the company’s stock valued at $55,992,000 after buying an additional 999,873 shares during the last quarter. Finally, Candriam S.C.A. increased its position in PROCEPT BioRobotics by 104.8% during the second quarter. Candriam S.C.A. now owns 63,125 shares of the company’s stock worth $3,636,000 after buying an additional 32,301 shares in the last quarter. Institutional investors and hedge funds own 89.46% of the company’s stock.

Key Headlines Impacting PROCEPT BioRobotics

Here are the key news stories impacting PROCEPT BioRobotics this week:

• Positive Sentiment: TD Cowen cut its price target to $34 but kept a “buy” rating, still implying material upside from current levels — a vote of confidence that the stock can recover if execution improves. TD Cowen Lowers PT to $34
• Positive Sentiment: PROCEPT hosted an Investor Day outlining a multi‑year strategic plan and 2026–2027 financial outlook aimed at driving long‑term growth, which could support sentiment if management delivers on targets. Investor Day Release
• Neutral Sentiment: Piper Sandler trimmed its target to $28 but kept an “overweight” rating — reduces upside expectations but maintains constructive stance. Piper Sandler PT Cut
• Neutral Sentiment: Oppenheimer reaffirmed a “market perform” rating, leaving some analyst views unchanged amid the mixed signals. Oppenheimer Reaffirms Rating
• Neutral Sentiment: Management’s FY‑2026 revenue guidance of $390M–$410M is slightly above consensus, which could be a modest positive if the company demonstrates trajectory toward those targets. FY‑2026 Guidance
• Negative Sentiment: Q4 results missed badly: EPS of ($0.53) vs. consensus ($0.32) and revenue $76.4M vs. $93.7M expected — a near‑term shock to expectations. Q4 Results & Call
• Negative Sentiment: Q1 revenue guidance was cut sharply to $79M–$82M (well below the ~$93.7M consensus), raising concerns about near‑term growth and driving the immediate sell‑off. Q1 Revenue Guide
• Negative Sentiment: Bank of America downgraded PRCT to “underperform” and cut its target to $20, reflecting increased downside risk from the earnings/guidance miss. BofA Downgrade
• Negative Sentiment: Coverage noting PRCT hit a 52‑week low highlights the market reaction to the mix of weak quarterly results and guidance. 52‑Week Low Coverage

About PROCEPT BioRobotics

PROCEPT BioRobotics, Inc is a medical device company specializing in the development and commercialization of robotic systems for the treatment of benign prostatic hyperplasia (BPH). The company’s technology leverages precision robotics and real-time imaging to perform minimally invasive procedures, aiming to reduce patient recovery time and improve clinical outcomes compared to traditional surgical approaches.

The company’s flagship product, the AquaBeam Robotic System, uses a high-velocity waterjet to selectively remove prostate tissue while preserving surrounding healthy structures.